Skip to main content
. 2020 Dec 13;17(6):1479164120975256. doi: 10.1177/1479164120975256

Figure 1.

Figure 1.

Cardiovascular outcomes, hospitalization for heart failure, and all-cause mortality by treatment group and LDL-cholesterol levels. Cox regression analysis in patients treated with ⩾1 dose of study drug: (a) 3-point MACE in subgroups by LDL-cholesterol at baseline, (b) CV death in subgroups by LDL-cholesterol at baseline, (c) hospitalization for heart failure in subgroups by LDL-cholesterol at baseline, and (d) all-cause mortality in subgroups by LDL-cholesterol at baseline.